We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease.
- Authors
Jang, Heejoon; Kim, Yeonjin; Lee, Dong Hyeon; Joo, Sae Kyung; Koo, Bo Kyung; Lim, Soo; Lee, Woojoo; Kim, Won
- Abstract
Key Points: Question: Among sodium-glucose cotransporter 2 (SGLT2) inhibitors, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, and sulfonylureas, which class of oral antidiabetic drugs (OADs) is the preferred therapeutic option for patients with both nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D)? Findings: In this nationwide cohort study involving 80 178 patients diagnosed with T2D and concurrent NAFLD in Korea, spanning 219 941 person-years, SGLT2 inhibitors were associated with a higher likelihood of NAFLD regression and lower incidence of adverse liver-related outcome parameters when compared with other OADs. Meaning: The results from this study suggest that SGLT2 inhibitors may be the preferred choice among OADs for individuals with both NAFLD and T2D, highlighting the need for additional research to determine whether a shift in prescribing practices is warranted. Importance: Several oral antidiabetic drug (OAD) classes can potentially improve patient outcomes in nonalcoholic fatty liver disease (NAFLD) to varying degrees, but clinical data on which class is favored are lacking. Objective: To investigate which OAD is associated with the best patient outcomes in NAFLD and type 2 diabetes (T2D). Design, Setting, and Participants: This retrospective nonrandomized interventional cohort study used the National Health Information Database, which provided population-level data for Korea. This study involved patients with T2D and concomitant NAFLD. Exposures: Receiving either sodium-glucose cotransporter 2 (SGLT2) inhibitors, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, or sulfonylureas, each combined with metformin for 80% or more of 90 consecutive days. Main Outcomes and Measures: The main outcomes were NAFLD regression assessed by the fatty liver index and composite liver-related outcome (defined as liver-related hospitalization, liver-related mortality, liver transplant, and hepatocellular carcinoma) using the Fine-Gray model regarding competing risks. Results: In total, 80 178 patients (mean [SD] age, 58.5 [11.9] years; 43 007 [53.6%] male) were followed up for 219 941 person-years, with 4102 patients experiencing NAFLD regression. When compared with sulfonylureas, SGLT2 inhibitors (adjusted subdistribution hazard ratio [ASHR], 1.99 [95% CI, 1.75-2.27]), thiazolidinediones (ASHR, 1.70 [95% CI, 1.41-2.05]), and DPP-4 inhibitors (ASHR, 1.45 [95% CI, 1.31-1.59]) were associated with NAFLD regression. SGLT2 inhibitors were associated with a higher likelihood of NAFLD regression when compared with thiazolidinediones (ASHR, 1.40 [95% CI, 1.12-1.75]) and DPP-4 inhibitors (ASHR, 1.45 [95% CI, 1.30-1.62]). Only SGLT2 inhibitors (ASHR, 0.37 [95% CI, 0.17-0.82]), not thiazolidinediones or DPP-4 inhibitors, were significantly associated with lower incidence rates of adverse liver-related outcomes when compared with sulfonylureas. Conclusions and Relevance: The results of this cohort study suggest that physicians may lean towards prescribing SGLT2 inhibitors as the preferred OAD for individuals with NAFLD and T2D, considering their potential benefits in NAFLD regression and lower incidences of adverse liver-related outcomes. This observational study should prompt future research to determine whether prescribing practices might merit reexamination. This cohort study investigates which oral antidiabetic drug was associated with the most advantageous outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes.
- Publication
JAMA Internal Medicine, 2024, Vol 184, Issue 4, p375
- ISSN
2168-6106
- Publication type
Article
- DOI
10.1001/jamainternmed.2023.8029